Drug targeting in cancer treatment: active daunorubicin-protein conjugates
Deprez-de Campeneere, D.; Masquelier, M.; Baurain, R.; Trouet, A.
Progress in Clinical and Biological Research 102 Pt A: 291-298
1982
ISSN/ISBN: 0361-7742 PMID: 7167441 Document Number: 183964
Document emailed within 1 workday
Related Documents
Wagner, G.; Oehlke, J. 1977: Mercaptopurine-protein-azoconjugates. 2. Acid and light sensitive structures in the conjugates. 13. Immunosuppressive agent-antigen conjugates Die Pharmazie 32(3): 157-162Wiernik, P.H.; Schimpff, S.C.; Schiffer, C.A.; Lichtenfeld, J.L.; Aisner, J.; O'connell, M.J.; Fortner, C. 1976: Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia Cancer Treatment Reports 60(1): 41-53
Sauer, H.; Ambrosius, H. 1978: Manipulations of immune reactions by antigen-immunosuppressive agent-conjugates. VI. Antigen specific binding of 6-mercaptopurine-protein conjugates by lymphocytes Acta Biologica et Medica Germanica 37(7): 1099-1103
Dwarakanath, B.S.; Verma, A.; Bhatt, A.N.; Parmar, V.S.; Raj, H.G. 2008: Targeting protein acetylation for improving cancer therapy Indian Journal of Medical Research 128(1): 13-21
Zhao, H.; Wang, Y.; Li, H. 2015: Cancer drug discovery targeting histone methyltransferases: an update Current Medicinal Chemistry 22(17): 2075-2086
Hungerford, N.L.; McKinney, A.R.; Stenhouse, A.M.; McLeod, M.D. 2006: Selective manipulation of steroid hydroxyl groups with boronate esters: Efficient access to antigenic C-3 linked steroid-protein conjugates and steroid sulfate standards for drug detection Organic and Biomolecular Chemistry 4(21): 3951-3959
Masters, D.B. 2002: Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices Official Gazette of the United States Patent and Trademark Office Patents 1254(5)
Sun, J.H.; Zhang, Y.H.; Kuang, J.Y.; Liu, G.; Liu, Y.X.; Liu, B.H. 2016: Active immunisation targeting soluble murine tumour necrosis factor alpha is safe and effective in collagen-induced arthritis model treatment Clinical and Experimental Rheumatology 34(2): 242-246
Maftouh, M.; Monsarrat, B.; Rao, R.C.; Meunier, B.; Paoletti, C. 1984: Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile Drug Metabolism and Disposition: the Biological Fate of Chemicals 12(1): 111-119
Saif, M.Wasif. 2013: U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer Jop: Journal of the Pancreas 14(6): 686-688
Lambin, P.; Landuyt, W. 2003: Vascular targeting: a potential additional anti-cancer treatment Verhandelingen - Koninklijke Academie Voor Geneeskunde van Belgie 65(1): 29-46
Dobre, V.; Maltezeanu, G. 1970: 3-N,N-bis(2-chloroethylamino)p-toluic acid, a new cytostatic drug active in cancer Cancer ChemoTherapy Reports 54(5): 319-323
Ogawa, Y.; Toguchi, H. 1990: Targeting therapy with a drug using temperature-sensitive liposomes entrapped antitumor drug together with localized hyperthermia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(6): 1127-1133
Arao, T.; Kudo, M.; Nishio, K. 2010: Searching for biological markers of molecular targeting treatment of liver cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(10): 1879-1882
Urasaki, Y.; Ueda, T.; Yoshida, A.; Fukushima, T.; Takeuchi, N.; Tsuruo, T.; Nakamura, T. 1996: Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms Anticancer Research 16(2): 709-714
Wang, Y.-j.; Cao, X.; Liu, X.-y.; Lu, X.-l.; Li, Y.-y.; Jiao, B.-h. 2016: Antibody-drug conjugates: design and clinical progress Yao Xue Xue Bao 51(8): 1209-1216
Guo, J.-j.; Gao, R.; Quan, T.-f.; Zhu, L.-y.; Shi, B.; Zhao, Y.-y.; Zhu, J.; Li, M.-s.; Bu, H.-z. 2015: Progress on pharmacokinetic study of antibody-drug conjugates Yao Xue Xue Bao 50(10): 1203-1209
Rothuizen, J.; van den Ingh, T. 1988: Covalently protein-bound bilirubin conjugates in cholestatic disease of dogs American Journal of Veterinary Research 49(5): 702-704
Malaĭtsev, V.V.; Azhipa, O.I. 1993: The effect of epitope density on the immunogenic properties of hapten-protein conjugates Biulleten' Eksperimental'noi Biologii i Meditsiny 115(6): 645-646
Ciekot, J.ła.; Goszczyński, T.; Boratyńskit, J. 2012: Methods for methotrexate determination in macromolecular conjugates drug carrier Acta Poloniae Pharmaceutica 69(6): 1342-1346